SCANCELL HLDGS (SCLP)
SCANCELL HLDGS (SCLP.L, LSE, LSE:SCLP)
SCLP Share PerformanceMore
|52 week high||45.240 01/06/15|
|52 week low||22.435 02/04/15|
|52 week change||-6.750 (-19.15%)|
|4 week volume||3,619,642 07/08/15|
Media for (SCLP)
Latest News« previous» nextMore
27/08/2015 - 16:42 RNS
RNS Number: 3587X Scancell Holdings Plc 27 August 2015 27 August 2015 Scancell Holdings Plc Notice of AGM Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting on Tuesday 20 October 2015. AGM details are as follows: Date: Tuesday 20 October, 2015 Time: 11.00...
31/07/2015 - 00:00 BRR Media
30/07/2015 - 07:00 RNS
RNS Number: 5007U Scancell Holdings Plc 30 July 2015 Scancell and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCkeR Nottingham, UK and Grenoble, France, 30 July 2015 - Scancell Holdings plc ('Scancell' LSE:AIM SCLP), the developer of novel immunotherapies for the treatment of cancer, and ImmunID, an immune molecular ...
09/07/2015 - 07:32 StockMarketWire
Scancell Holdings has closed patient recruitment for its SCIB1 ImmunoBody Phase 1/2 clinical trial in patients with Stage II...
09/07/2015 - 07:00 RNS
RNS Number: 5588S Scancell Holdings Plc 09 July 2015 09 July 2015 Scancell Holdings Plc Patient recruitment completed for SCIB1 Phase 1/2 clinical trial SCIB1 continues to deliver strong survival data in resected melanoma patients with Stage III/IV disease Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of ...
02/06/2015 - 15:23 Motley Fool
Shares in pharmaceutical company, Scancell (LSE:SCLP), have fallen by as much as 10% today despite the company provid...
02/06/2015 - 10:06 StockMarketWire
Scancell Holdings confirms further encouraging results from its on-going Phase 1/2 clinical trial of SCIB1, its DNA Immun...
02/06/2015 - 07:00 RNS
RNS Number: 8686O Scancell Holdings Plc 02 June 2015 2 June 2015 Scancell Holdings Plc Scancell provides positive update on SCIB1 data in resected melanoma patients Median survival time of 34 and 31 months for Stage III and IV patients Scancell Holdings plc ('Scancell' or the 'Company'), the developer of novel immunotherapies for the treatment of cancer, is pleased...
|Dividend yield||0 %|
Latest discussion posts More
Codes & Symbols
|Symbols||SCLP, LSE:SCLP, SCLP.L, SCLP:LN, LON:SCLP, XLON:SCLP|